All Posts

Summary There are four common indications seen in Q2 Big/Suspected Movers NASH/Liver disease, kidney disease, eye disease, and mental...

Summary: Q1 2023 quarterly financial reports have started! Many large cap biotechs have already reported, and we expect most of the...

First published 5/5/23 Summary: The American Society of Clinical Oncology Annual Meeting is taking place from June 2-6, 2023 This annual...

First published 4/19/23 Summary: AACR wrapped up today with just a couple presentations and investor calls Which companies performed best...

Summary: As we are almost in the last week of April, many PDUFA decisions are still to come! Next week will be busy for PDUFAs, with 6...

AACR kicked off this weekend. 8 PDUFA events left in April. Other meeting/events happening as well. See the full table below. Connect...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: Every quarter we look at the 36 life science hedge funds to determine patterns and to see which tickers are most held by hedge...

The first week of April didn't have too many major events, although $IFRX did move +183% on Emergency Use Authorization. Looking forward,...